HDAC inhibitors target IRS4 to enhance anti?AR therapy in AR?positive triple?negative breast cancer. He Y, Ma Y, Zhu Y, Zhang J, et al. Int J Oncol 2024;64:25.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

He Y, Ma Y, Zhu Y, Zhang J, et al. HDAC inhibitors target IRS4 to enhance anti?AR therapy in AR?positive triple?negative breast cancer. Int J Oncol 2024;64:25.
PMID: 38214343